Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
N Engl J Med 380(24):22952306 Kristensen SL, Rrth R, Jhund PS, Docherty KF, Sattar N, Preiss D et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
The major adverse cardiovascular events non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (3-point MACE), and all-cause mortality, were ascertained from detailed prospectively collected data at regular assessments and validated linked administrative databases
Public discourse surrounding GLP-1RAs thus remains dynamic and unsettled
Variants in GIPR (rs1800437 is the headline variant for differential GLP-1 response), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide
